Access cutting-edge retinitis pigmentosa treatment through this clinical trial at a research site in Oak Park. Study-provided care at no cost to qualified participants.
Access retinitis pigmentosa specialists in Oak Park at no cost
This study follows strict safety protocols and ethical guidelines
All study-related retinitis pigmentosa treatment provided free
This study evaluates the safety of a single injection of jCell (famzeretcel) comprising 8.8 million (8.8M) retinal progenitor cells over a six-month study period in a cohort of adult subjects with RP. Additionally, changes in visual function will be evaluated at six months between the active treatment group (8.8M jCell) compared to sham-treated controls.
Sponsor: jCyte, Inc
Check if you qualify for this retinitis pigmentosa clinical trial in Oak Park, IL
If you're searching for retinitis pigmentosa treatment options in Oak Park, IL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Oak Park research site is actively enrolling participants for this clinical trial. You'll receive care from experienced retinitis pigmentosa specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.